The present paper will focus on the role of one specific MDR protein, ABCG2, in AML, summarizing the current knowledge on the impact of its overexpression on disease outcome and on the possibility to counteract its action to improve the efficacy of anti-leukemic therapies. Here, ABCG2 is linked to acute myeloid leukemia.